Singapore, Apr 22, 2010: Chinese firm Simcere Pharmaceutical said that its diosmectite, the Active Pharmaceutical Ingredient (API) in its branded generic drug Biqi, has passed EU-GMP inspection. This enables Simcere to market diosmectite in the EU.
 
Simcere has been manufacturing and marketing diosmectite API and formulation under the Biqi brand name for many years in China. Diosmectite is made from a natural mineral material and its formulation is the leading anti-diarrheal drug in China and France. Simcere owns a high grade diosmectite mine in China.
 
Mr Jinsheng Ren, Chairman and CEO of Simcere Pharmaceutical Group, termed this development as an important start in driving the company's international business.